 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...1213141516171819202122...170171» |
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens. (Pubmed Central) - Aug 18, 2023
Use of apixaban or rivaroxaban in a triple antithrombotic regimen was not associated with bleeding or ischemic outcomes.
- | rivaroxaban / Generic mfg.
Retrospective data, Journal: Exploring safety and efficacy of rivaroxaban after living donor liver transplantation: a retrospective study. (Pubmed Central) - Aug 18, 2023
Rivaroxaban may be a safe and effective alternative in LDLT recipients with no significant adverse incidents. Further studies with larger sample sizes are needed to confirm these findings and determine this population's optimal dose and duration of rivaroxaban therapy.
- || Savaysa (edoxaban) / Daiichi Sankyo
Review, Journal: Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. (Pubmed Central) - Aug 18, 2023
This review article provides an overview of current knowledge on the selection and dose of DOACs including apixaban, dabigatran, edoxaban and rivaroxaban in AF patients at different stages of renal insufficiency, with a special focus on elderly patients with comorbidities and receiving multiple medications. The groups discussed in this review include patients with varying levels of CrCl including hyperfiltration or CrCl?>?90
- | rivaroxaban / Generic mfg.
Retrospective data, Journal: Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF. (Pubmed Central) - Aug 16, 2023
P3
In COMMANDER-HF a diagnosis of diabetes conferred higher rates of cardiovascular events that, with exception of ischaemic stroke, was not substantially reduced by rivaroxaban. Rivaroxaban was associated with reduced risk of ischaemic stroke for patients with and without diabetes.
- || Savaysa (edoxaban) / Daiichi Sankyo
Review, Journal: Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20?Years: A Bibliometric Analysis Via CiteSpace and VOSviewer. (Pubmed Central) - Aug 16, 2023
Studies during 2017 to 2022 focused on apixaban, direct oral anticoagulant, rivaroxaban, dabigatran, hemorrhage, edoxaban, medicine efficacy and safety, risk factors, clinical management, and vitamin K antagonists...On the whole, most studies of AF and VTE focus on pathogenesis and therapeutic drugs. The causal relationship between AF and VTE, the effectiveness and safety of novel oral anticoagulants in the treatments, the anticoagulant regimen of AF and VTE co-disease, and the treatment regimen for vulnerable populations such as the elderly or obese people were the focus of current research and will continue to be the central point of future research.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal, Real-world evidence, Real-world: Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin. (Pubmed Central) - Aug 16, 2023
The safety of warfarin could be better than rivaroxaban in patients with CKD with fewer bleeding complications but similar stroke rates. Further studies on rivaroxaban dosing in patients on dialysis are required.
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program. (Pubmed Central) - Aug 16, 2023
Directionally similar results to those at 3 months were observed at 6 months for all outcomes. In conclusion, we observed fewer recurrent VTE cases and no increase in bleeding-related hospitalizations with rivaroxaban versus LMWH at 3 months in this patient cohort with various cancer types.
- | rivaroxaban / Generic mfg.
Journal: Buddi-Chiari syndrome associated with hypereosinophilic syndrome: A case report. (Pubmed Central) - Aug 15, 2023
The patient, in this case, was finally diagnosed with BCS combined with hypereosinophilic syndrome, and to our knowledge, such case reports are rare. Our case report suggest an association between BCS and hypereosinophilic syndrome, but relevant studies are minimal, we hope to conduct larger and higher quality studies on these patients in the future, to provide new directions and basis for the etiology and pathogenesis of these diseases, as well as provide new targets and ideas for clinical treatment.
- ||| Savaysa (edoxaban) / Daiichi Sankyo
Journal, Adverse events, Adverse drug reaction: Identification of risk factors for adverse drug reactions in a pharmacovigilance database. (Pubmed Central) - Aug 15, 2023
We demonstrated that data mining within a pharmacovigilance database identifies known risk factors for DOAC bleeding, and potential risk factors such as dementia and atrial fibrillation. We propose that the method could be used in pharmacovigilance for identification of potential ADR risk factors that merit further evaluation.
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban attenuates neutrophil maturation in the bone marrow niche. (Pubmed Central) - Aug 14, 2023
In translation, ST-elevation MI patients treated with rivaroxaban also exhibited reduced circulating leukocyte numbers. In conclusion, we demonstrate that rivaroxaban attenuates neutrophil maturation in the BM, which may offer a therapeutic option to limit overshooting of the immune response after I/R.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Observational data, Retrospective data, Journal: Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study. (Pubmed Central) - Aug 14, 2023
A notable proportion of patients with VTE who were mostly at low to intermediate risk of bleeding received non-recommended doses or durations of apixaban or rivaroxaban for lead-in therapy. Large studies are needed to establish evidence about the outcomes associated with these practices.
- | rivaroxaban / Generic mfg.
Journal: Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism. (Pubmed Central) - Aug 14, 2023
A morbidly obese woman in her 30s who presented with acute worsening of dyspnea was diagnosed with acute intermediate-high risk acute pulmonary embolism and concomitant proximal deep vein thrombosis, constituting a clinically challenging scenario for treating her with rivaroxaban. Standard doses of rivaroxaban for acute and extended phase treatment of venous thromboembolism in individuals with morbid obesity at BMI>70 kg/m may be effective, and safe.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Synergistic Influence of Rivaroxaban on Platelets, Inflammation and Coagulation Biomarkers in Patients With CAD and/or PAD on Aspirin Therapy (Zone 4, Science and Technology Hall, Level 200) - Aug 12, 2023 - Abstract #AHA2023AHA_4981;
Standard doses of rivaroxaban for acute and extended phase treatment of venous thromboembolism in individuals with morbid obesity at BMI>70 kg/m may be effective, and safe. Abstract is embargoed at this time.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Impact of Low-Dose Rivaroxaban Plus Aspirin on Total Vascular Events in Fragile Patients With Peripheral Artery Disease: Insights From VOYAGER PAD (103B) - Aug 12, 2023 - Abstract #AHA2023AHA_3737;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Impact of Low-Dose Rivaroxaban Plus Aspirin on Myocardial Infarction in Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD (Zone 1, Science and Technology Hall, Level 200) - Aug 12, 2023 - Abstract #AHA2023AHA_340;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- rivaroxaban / Generic mfg.
Effectiveness of Low-Dose Rivaroxaban in Preventing Recurrent Major Adverse Cardiovascular Events in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Zone 4, Science and Technology Hall, Level 200) - Aug 12, 2023 - Abstract #AHA2023AHA_306;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- || Review, Journal: DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives. (Pubmed Central) - Aug 12, 2023
However, rivaroxaban was successful in two small clinical trials. Ample research is still needed to explore new valve designs as well as new anticoagulation targets.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal: Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study. (Pubmed Central) - Aug 12, 2023
Among subjects taking apixaban, rivaroxaban, and dabigatran, the smallest representation of patients who achieved therapeutic concentrations were those treated with dabigatran. The population of people with abnormal body weight is a potential risk group of patients, in which some of them do not reach the therapeutic range of DOACs.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Reimbursement, US reimbursement, Journal, Medicare: Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke. (Pubmed Central) - Aug 12, 2023
The population of people with abnormal body weight is a potential risk group of patients, in which some of them do not reach the therapeutic range of DOACs. Increased OOP costs during Medicare coverage gap were associated with higher risk of DOAC discontinuation, which in turn was associated with higher risk of stroke and SE among beneficiaries with NVAF.
- || Retrospective data, Review, Journal: The Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation: A Network Meta-Analysis. (Pubmed Central) - Aug 11, 2023
In terms of safety, apixaban was also found to be the most favorable treatment option, followed by rivaroxaban, dabigatran, and warfarin. In summary, our study concludes that apixaban exhibited greater effectiveness and safety when compared to other DOACs and warfarin in obese patients with AF.
- | rivaroxaban / Generic mfg.
Journal: Follow-up study of isolated calf muscular vein thrombosis for anticoagulant therapy after primary hip and knee arthroplasty. (Pubmed Central) - Aug 7, 2023
In summary, our study concludes that apixaban exhibited greater effectiveness and safety when compared to other DOACs and warfarin in obese patients with AF. Our findings provide new insights into the anticoagulant therapy for ICMVT after primary hip and knee arthroplasty, taking oral Rivaroxaban for 3
- | rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Reimbursement, US reimbursement, Journal: Reimbursement and use of oral anticoagulants during 2014-2022 - A register-based study. (Pubmed Central) - Aug 4, 2023
The number of warfarin users declined since 2015 from over 181,000 to around 59,000 users in 2022, DOACs exceeding warfarin in the number of users in 2019...Rivaroxaban was the most widely used DOAC during 2014-2018, and apixaban during 2019-2022...During the 2010s, the treatment guidelines for AF were more cautious in recommending DOACs than the European guidelines. The use of DOACs increased as their reimbursement became less restrictive.
- EMBOLIC STROKE OF UNKNOWN SOURCE: A TREATMENT CONUNDRUM (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_5241;
- A RARE PULMONARY EMBOLISM MIMIC (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_5159;
- DO RENAL CYSTS HEIGHTEN THE RISK OF SPONTANEOUS RENAL HEMATOMA IN PATIENTS WITH ANTICOAGULANT USE? (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_5147;
- EOSINOPHILIC MYOCARDITIS MANIFESTING AS DECOMPENSATED HEART FAILURE WITH THROMBI (Convention Center Exhibit Hall - Rapid Area 2B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4794;
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
ASSOCIATION OF RIVAROXABAN VS APIXABAN IN BASELINE ACT FOR UNINTERRUPTED AFIB ABLATION AND PROCEDURE COMPLICATIONS: SINGLE CENTER RETROSPECTIVE STUDY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4177;
- THE IMPACT OF ANTI-COAGULATION USE ON THE RISK OF HEMORRHAGIC TRANSFORMATION OF ISCHEMIC STROKE IN PATIENTS WITH DEEP VEIN THROMBOSIS (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3821;
- ANTI-COAGULATION CHOICE IN PATIENTS WITH PULMONARY EMBOLISM AND ACUTE ISCHEMIC STROKE (Convention Center Exhibit Hall - Rapid Area 2A) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3680;
- COMPLETE ATRIOVENTRICULAR BLOCK: A RARE PRESENTATION OF ACUTE SUBMASSIVE PULMONARY EMBOLISM (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3477;
- RECURRENT DEEP VEIN THROMBOSIS WITH PULMONARY EMBOLISM DUE TO FAILURE OF DIRECT ORAL ANTICOAGULANT AGENTS IN A MORBIDLY OBESE PATIENT WITH PROTHROMBIN G20210A MUTATION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3410;
- A CASE OF PULMONARY AND CUTANEOUS INVOLVEMENT OF LYMPHOMATOID GRANULOMATOSIS IN IMMUNOCOMPETENT FEMALE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3297;
- RIGHT VENTRICLE THROMBUS IN-SITU ON THE RIGHT VENTRICLE WALL (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3110;
- HYPERAMMONEMIC ENCEPHALOPATHY IN PATIENT WITH MULTIPLE MYELOMA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3102;
- MECHANICAL THROMBECTOMY AFTER FAILED SYSTEMIC THROMBOLYSIS (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3020;
- A CRYPTOGENIC PAIN IN THE GUT: A CASE OF PRESSURE-DEPENDENT ATRIAL SEPTAL DEFECT WITH EMBOLI CAUGHT IN-TRANSIT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3003;
- PARADOXICAL THROMBOEMBOLISM THROUGH A PATENT FORAMEN OVALE: A CASE REPORT OF LOWER EXTREMITY DVT LEADING TO MYOCARDIAL INFARCTION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2826;
- rivaroxaban / Generic mfg.
POOR RESPONSE TO RIVAROXABAN IN A PATIENT WITH NEPHROTIC SYNDROME AND VENOUS THROMBOEMBOLISM (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2503;
- dapsone / Generic mfg.
A RARE CASE OF DAPSONE-INDUCED METHEMOGLOBINEMIA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2495;
- CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS) DIAGNOSED POST-MORTEM: LESSONS LEARNED (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2492;
- PERICARDIOCUTANEOUS FISTULA FORMATION AS A RARE COMPLICATION OF RECURRENT PERICARDIOCENTESIS (Convention Center Exhibit Hall - Rapid Area 2B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2364;
- FOCAL FIBROSING MEDIASTINITIS PRESENTING WITH SUPERIOR VENA CAVA SYNDROME (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2291;
- SPONTANEOUS PNEUMOMEDIASTINUM IN A NON-MECHANICALLY VENTILATED PATIENT WITH PROLONGED COVID-19: PATIENT SELF-INFLICTED LUNG INJURY (P-SILI)? (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2276;
- rivaroxaban / Generic mfg.
RIVAROXABAN FAILURE IN HIGH THROMBOTIC RISK: THE STORY OF A SHOCKING STROKE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2096;
- ACUTE AORTIC THROMBUS COMPLICATED WITH SPLENIC INFARCTION IN A COVID-19 PATIENT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2060;
- AN UNCOMMON COMPLICATION: TRANSDIAPHRAGMATIC EXTENSION OF A HEPATIC ABSCESS LEADING TO EMPYEMA (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1898;
- A RARE CASE OF LIBMAN-SACKS ENDOCARDITIS REQUIRING BIOPROSTHETIC VALVE REPLACEMENT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1841;
- A CASE OF MISTAKE IDENTITY: PERSISTENT PULMONARY EMBOLISM SYMPTOMS PROMPT A SECONDARY INVESTIGATION (Convention Center 317B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1729;
- A CASE OF PAGET SCHROETTER SYNDROME WITH PULMONARY EMBOLISM SECONDARY TO COMPETITIVE VIDEO GAMING (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1632;
- CLOT-ASTROPHE AVERTED: SUCCESSFUL THROMBECTOMY IN A PATIENT WITH A RIGHT HEART THROMBUS, PULMONARY EMBOLISM, AND BIVENTRICULAR FAILURE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1627;